Pfizer and GlaxoSmithKline Combat Melanoma An announcement was made by pharmaceutical giants Pfizer and GlaxoSmithKline at the end of November 2013 regarding their agreement to combine efforts in researching a novel melanoma treatment. The clinical study the two companies have commenced involves adult patients with unresectable, metastatic melanoma. This partnership will be a Phase I/II[…]
New Trametinib and Palbociclib Combo Drug for Melanoma Being Studied
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Breakthrough Therapy Status Tags: GlaxoSmithKlineMekinistmelanomametastatic breast cancermetastatic melanomaPfizerTrametinib Dec 17, 2013
FDA Approves Everolimus for Advanced Breast Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News, Immunosuppressant Tags: 159351-69-6breast cancerEverolimusmetastatic breast cancerPfizer Jul 20, 2012
Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease. Everolimus CAS# 159351-69-6, is the active ingredient for Afinitor®. Click for more information on, and availability of Everolimus. Also, click for more articles on breast cancer and the HER2 receptor. The approval was based on a[…]
The Need for Anthracyclines Grows
Anthracycline, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, TEVA API Tags: acute lymphoblastic leukemiaAnthracyclinesmetastatic breast cancer Jun 06, 2012
The latest headline is daunting, with the World Health Organization’s International Agency for Research on Cancer announcing a 75 percent increase in cancer cases worldwide by 2030. This astounding prediction, published in Reuters on June 1, 2012 offered an unfortunate reality, based on data from GLOBOCAN. Causes are thought to be poor lifestyle choices worldwide,[…]
Lapatinib Ditosylate and the Power of Cancer Fighting Kinase Inhibitors
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2010 Tags: kinase inhibitormetastatic breast cancer Apr 05, 2012
As a kinase inhibitor, Lapatinib Ditosylate, CAS number 388082-78-8 is efficacious when used to treat metastatic breast cancer. The ability of lapatinib ditosylate to inhibit deviating active kinases within cancer cells, and prevent cell division, makes it an effective choice for patients with advanced breast cancer. Also known as Tykerb, which is marketed by GlaxoSmithKline,[…]
